Delenex completes its management team
Thomas Jung becomes chief medical officer
A board certified dermatologist, Jung has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel, Switzerland.
In January 2008 he took leadership of the Ilaris development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.
Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.
Eric de La Fortelle, ceo of Delenex, said: ‘With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programmes to bring its major new compounds to clinical proof of concept.’
You may also like
Manufacturing
IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility
Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for US-based aseptic fill-finish services
Manufacturing
Cellistic launches three new iPSC-based GMP platforms to advance immuno-oncology and regenerative therapies
The three new iPSC-derived GMP manufacturing platforms, Echo-T, Echo-Cardio and Echo-Endothelial, expand the company’s Echo portfolio and are designed to improve scalability and manufacturability across immuno-oncology and regenerative medicine programmes
Manufacturing
The role of vacuum drying in battery manufacturing: From precursors to cell assembly
Lithium-ion battery manufacturers place enormous emphasis on material purity, structural integrity, and process control. Vacuum drying, used at both the precursor and electrode stages, has become an important step in achieving these performance and safety targets. Let’s explore where and how vacuum drying fits into modern battery production and how Powder Systems Ltd’s tray drying technology supports this growing need
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Manufacturing
Jubilant Biosys doubles chemistry capacity with new Noida facility in India
The company has announced the opening of a new discovery and preclinical facility in Noida, combining discovery and early-phase scale-up capabilities with R&D labs and two pilot plants to meet growing demand for FFS contracts